Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis

This is a study evaluating the efficacy of Ankaferd Blood Stopper (ABS) as a hemostatic agent compared to hemostasis by phenylephrine in patients with anterior epistaxis. The study design is a prospective, randomized, controlled, nonblinded, clinical trial. In total, 49 patients were randomly sepera...

Full description

Saved in:
Bibliographic Details
Published in:European archives of oto-rhino-laryngology 2010-09, Vol.267 (9), p.1377-1381
Main Authors: Meric Teker, Aysenur, Korkut, Arzu Yasemin, Kahya, Volkan, Gedikli, Orhan
Format: Article
Language:English
Subjects:
Administration, Intranasal
Adult
Biological and medical sciences
Cross-Over Studies
Epistaxis - blood
Epistaxis - classification
Epistaxis - drug therapy
Female
Head and Neck Surgery
Hemostatics - administration & dosage
Humans
International Normalized Ratio
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Neurosurgery
Non tumoral diseases
Otorhinolaryngology
Otorhinolaryngology. Stomatology
Phenylephrine - administration & dosage
Plant Extracts - administration & dosage
Prospective Studies
Recurrence
Retreatment
Rhinology
Risk Factors
Tampons, Surgical
Turkey
Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This is a study evaluating the efficacy of Ankaferd Blood Stopper (ABS) as a hemostatic agent compared to hemostasis by phenylephrine in patients with anterior epistaxis. The study design is a prospective, randomized, controlled, nonblinded, clinical trial. In total, 49 patients were randomly seperated to receive hemostasis technique by means of either ABS wet tampon or phenylephrine impregnated gauze tampon for anterior epistaxis control. Patients were crossed over to the other technique after two unsuccessful attempts of the first technique. Measured outcomes such as number of applications, relationship of number of applications with bleeding intensity (1 = stains on napkin, 2 = soaked napkin, 3 = bowl needed), patient discomfort during hemostasis (0 = none, 9 = unbearable), and complications were assessed. Additional data were recorded for rebleeding within 7 days. 24 of the 49 patients were assigned to the new ABS group (group I) and remaining 25 were included in the standard phenylephrine group (group II). ABS was more effective than phenylephrine at control of anterior epistaxis (79.2 vs. 64%, p  
ISSN:0937-4477
1434-4726
DOI:10.1007/s00405-010-1208-0